CCA
PTCT icon

Column Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Column Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-72
Closed -$3K – 775
2019
Q4 		$3K Buy
+72
New +$3.06K ﹤0.01% 587

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Column Capital Advisors's PTCT Position: Q1 2020 in Review

Column Capital Advisors sold out of PTC Therapeutics (PTCT) in Q1 2020, closing a stake of 72 shares — an estimated $3K sold.

Column Capital Advisors first reported a position in PTCT in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 202 funds tracked by Wall St. Rank hold PTCT as of Q1 2020.

  • Column Capital Advisors reported no remaining PTC Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Column Capital Advisors sold 72 PTC Therapeutics shares in Q1 2020, an estimated $3K.
  • Column Capital Advisors first reported a position in PTC Therapeutics in Q4 2019 and held it in 1 quarter.
  • Column Capital Advisors's PTC Therapeutics position peaked at $3K in Q4 2019.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2020.

Based on Column Capital Advisors's 13F filing for Q1 2020, filed 11 May 2020.